A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer
Ken‐Pin Hwang(The University of Texas MD Anderson Cancer Center), Gaiane M. Rauch(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Alastair M. Thompson(Baylor College of Medicine), Rania M. Mohamed(The University of Texas MD Anderson Cancer Center), Bikash Panthi(The University of Texas MD Anderson Cancer Center), Jong Bum Son(The University of Texas MD Anderson Cancer Center), Jia Sun(Nanjing University of Chinese Medicine), Clinton Yam(The University of Texas MD Anderson Cancer Center), Rosalind P. Candelaria(The University of Texas MD Anderson Cancer Center), Aikaterini Kotrotsou(The University of Texas MD Anderson Cancer Center), Benjamin C. Musall(Henry Ford Health System), Beatriz E. Adrada(The University of Texas MD Anderson Cancer Center), Nabil Elshafeey(The University of Texas MD Anderson Cancer Center), Wei Yang(Shanghai Jiao Tong University), Elizabeth E. Ravenberg(Eli Lilly (United States)), Medine Böge(The University of Texas MD Anderson Cancer Center), Shu Zhang(Healthwise), Jingfei Ma(The University of Texas MD Anderson Cancer Center), Huiqin Chen(Soochow University), Mark D. Pagel(University of Wisconsin–Madison), Abeer H. Abdelhafez(The University of Texas MD Anderson Cancer Center), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Lei Huo(The University of Texas MD Anderson Cancer Center)
Cited by 32
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k